The European Commission has granted conditional marketing authorization (Aic) for idecabtagene vicleucel (Ide-cel), the first T-cell based immunotherapy with chimeric antigen receptor (Car-T) directed against maturation antigen B cell (Bcma), for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and who have demonstrated disease progression to the last therapy. This was announced by Bristol Myers Squibb (Bms), noting that Ide-cel is the first and only approved Car-T therapy aimed at recognizing and binding to Bcma, a protein almost universally expressed on multiple myeloma cells, killing diseased cells.
Read Also
- Canada will decriminalize hard drugs in the province of British Columbia as part of a pilot project Jun 1, 2022
- A study discovers the protective effect of moderate consumption of eggs in cardiovascular diseases May 29, 2022
- The Lakers complicate their lives May 31, 2021
- Delta variant, vaccine symptoms: how to recognize the signs of the disease Jul 8, 2021
- How to wash your hands during a pandemic Mar 26, 2020
- Moderna says her vaccine is safe and effective for teens May 28, 2021
- Ontario reported 640 new COVID-19 cases on Saturday Sep 25, 2021